ArticleCureus2025
Silent Yet Striking: Medullary Carcinoma Behind an Intestinal Obstruction.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinoma of the ascending colon, especially the medullary type, is a rare and poorly differentiated form of colorectal cancer. This case report details a case of a 75-year-old woman with a background of cardiovascular issues, hypertension, and dementia who presented with complete large bowel obstruction and was found to have poorly differentiated carcinoma of the ascending colon with medullary features. The surgical approach involved an exploratory laparotomy followed by a right hemicolectomy. The pathological analysis confirmed a pT3N0M0, G3 stage II tumor, characterized by a loss of MLH1 and PMS2 protein expression, indicating microsatellite instability (MSI-H). Since there was no nodal involvement, adjuvant chemotherapy wasn't deemed necessary. The patient was encouraged to keep up with regular follow-ups, which would include monitoring carcinoembryonic antigen (CEA) levels, a complete metabolic panel (CMP), a complete blood count (CBC), and CT imaging every six months and annually. Although CEA is the most established tumor marker in colorectal cancer, it is still part of the follow-up plan, owing to its lack of sensitivity in the medullary subtype. In addition to this, the recommendation was for a surveillance colonoscopy every three years. This report sheds light on the case's pathological, clinical, and follow-up elements, emphasizing the need for personalized patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.